FDG-PET tech ctte

From QIBA Wiki

Jump to: navigation, search

Contents

Quantitative FDG-PET Technical Committee Mission

  • Mission; Foster adoption of ...
    • pragmatic and cost effective standards for
    • accurate and reproducible
    • longitudinal
    • quantitation of
    • biologic parameters
    • with clinical relevance
    • and known sigma

Meetings / Call Summaries

PET Amyloid Profile Writing Group

UPICT Protocol Development

FDG-PET Reporting Standards Writing Group

Problem Statement: • Gap between what is reported and what is needed for meta-analysis to determine value of quantitative imaging biomarkers • This is now established in the literature

Group members as of 5/27/2014:

  • Paul Kinahan, PhD (Co-Chair)
  • Paul Marsden, PhD (Co-Chair)
  • Sally F. Barrington, MD
  • Anastasia Chalkidou, MD
  • Dominique Delbeke, MD, PhD
  • Constantine Gatsonis, PhD
  • Otto Hoekstra, MD, PhD
  • Erich Huang, PhD
  • Lisa McShane, PhD
  • Dan Sullivan, MD
  • Richard L. Wahl, MD


Documents / Call Summaries

Profile Development

FDG-PET Profile Public Comment Phase - Association Dissemination List 11-April-2013

Public Comment:

Public Comment Version and Feedback Process - FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy
QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v1.04) Reviewed Draft (Public Comments Addressed) 06NOV2013
QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v1.04) Version for Public Comment 01AUG2013
QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v1.04) Summary of Open Public Comment Items for Resolution 01AUG2013
QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v1.03) Version for Public Comment 09MAR2013
QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v1.02) Version for Public Comment 21FEB2013
QIBA Profile: FDG-PET Whole Body v1.03 - Public Comment Summary - Updated 09MAR2013


Drafting:

Research Papers Analyzing FDG-PET Test-Retest Variability

  • Hatt M, Cheze-Le Rest, C, Aboagye EO, et al. Reproducibility of 18F-FDG and 3'-Deoxy-3'-18F-Fluorothymidine PET Tumor Volume Measurements. The Journal of Nuclear Medicine2010; 51(9):1368-1376. [1]
  • Kamibayashi T, Tsuchida T, Demura Y, et al. Reproducibility of Semi-quantitative Parameters in FDG-PET Using Two Different PET Scanners: Influence of Attenuation Correction Method and Examination Interval. Academy of Molecular Imaging 2008; 10:162-166.[2]
  • Krak NC, Boellaard R, Hoekstra OS, et al. Effects of ROI Definition and Reconstruction Method on Quantitative Outcome and Applicability in a Response Monitoring Trial. European Journal of Nuclear Medicine and Molecular Imaging 2005; 32(3):294–301.[3]
  • Minn H, Zasadny KR, Quint LE, Wahl RL. Lung Cancer: Reproducibility of Quantitative Measurements for Evaluating 2-[F-18]-Fluoro-2-deoxy-D-glucose Uptake at PET1. Radiology 1995; 196:167-173.[4]
  • Nahmias C, Wahl LM. Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors. The Journal of Nuclear Medicine 2008; 49(11):1804-1808. [5]
  • Nakamoto Y, Zasadny KR, Heikki M, Wahl RL. Reproducibility of Common Semi-quantitative Parameters for Evaluating Lung Cancer Glucose Metabolism with Positron Emission Tomography Using 2-Deoxy-2-[18F] Fluoro-D-Glucose. Molecular Imaging and Biology 2002; 4(2):171-178. [6]
  • Velasquez, LM, Boellaard R, Kollia G, et al. Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies. The Journal of Nuclear Medicine 2009;50:1646-1654. [7]
  • Weber WA, Ziegler SI, Thodtmann R, et al. Reproducibility of Metabolic Measurements in Malignant Tumors Using FDG PET. The Journal of Nuclear Medicine 1999; 40(11):1771-1777. [8]


Working Documents and Reference Materials

The Netherlands Standardization Protocol for Quantitative FDG-PET in Multi-center Trials (English translation of Version 1)

Please keep the following in mind:

The development of this protocol was started about 2005 and approved more than 1 year ago in The Netherlands (NL). However, with gained insight, changes are scheduled to be incorporated in the next version by 2010. The following changes will be made (consider them being applied already or underway):

  • Use of oral contrast is now excluded but will be allowed in the next version
  • We are currently working on standards for CT as well, including GL for doing CT-QC (in cooperation with the radiologists/radiology societies in NL)
  • There will be an upper limit for dosage
  • We are working on traceable/calibrated and mutually linked sources for both PET and the dose calibrator and these will be used for absolute (rather than cross-) calibration (but in addition to the cross-calibration using FDG).
  • Reconstruction settings given in the protocol are indicative and are likely not applicable for future scanners and software upgrades. Therefore reconstruction parameters should be set such that they provide results that meet the specifications given for the multi-center QC experiments. Same settings should then be applied to patient studies (see also comments under "execptions/special features” and comments made in the paper by Boellaard et al. EJNMMI 2008).
  • Various other minor edits/typos/changes

The protocol is not a step-by-step description of the logistics for doing a PET/CT study. However, it has been set up in a somewhat chronological order and may thus be used to populate (copy-paste) such a step-by-step description. Additional work required ... FDG-PET/CT Technical Committee input is highly appreciated.

Submitted by Ronald Boellaard, PhD

Submitted by Richard L. Wahl, MD and Martin A. Lodge, PhD

Submitted by Eric S. Perlman, MD

Slide Presentations

Round 1 of QIBA Funded Projects

Round 2 of QIBA Funded Projects

Personal tools